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Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing
Interleukin-12 and B7-1in an Immunocompetent MurineModel
Young-Sook Lee,1,2 Joo-Hang Kim,1,2 Kyung-Ju Choi,1,2 Il-Kyu Choi,1,2 Hoguen Kim,1,3 Sungae Cho,4
Byoung Chul Cho,2 and Chae-Ok Yun1,2
Abstract Purpose:We investigated whether an armed viral platform, where lytic property of a viral infec-
tion is coupled to viral-mediated delivery of therapeutic genes, could increase the therapeutic
potential of a viral-based therapy.
Experimental Design:We generated interleukin (IL)-12-expressing oncolytic adenovirus (YKL-
IL-12) and IL-12- and B7-1-expressing (YKL-IL12/B7) oncolytic adenovirus.Therapeutic efficacy
of these newly engineered adenoviruses was then evaluated in vivo using an immunocompetent
mouse bearing murine melanoma B16-F10 tumors. Overall survival was assessed with the
Kaplan-Meier method. The induction of immune cell cytotoxicity was assessed by CTL assay,
IFN-g enzyme-linked immunospot assay, and immunohistochemical studies.
Results:YKL-IL12/B7 oncolytic adenovirus, expressing both IL-12 and B7-1, showed a higher
incidence of complete tumor regression compared with the analogous oncolytic adenovirus,
YKL-1, or IL-12-expressing,YKL-IL12. Significant survival advantage was also seen in response to
YKL-IL12/B7. Moreover, IL-12 and IFN-g levels produced in tumors treated withYKL-IL12/B7
was significantly greater than those treated withYKL-IL12. The enhanced survival advantage
was mediated by the induction of immune cell cytotoxicity. In agreement with these results,mas-
sive infiltration of CD4+ and CD8+ Tcells into tissues surrounding the necrotic area of the tumor
was observed following in situ delivery ofYKL-IL12/B7.
Conclusion: Combination of oncolysis and the enhancement of antitumor immune response by
oncolytic adenovirus expressing both IL-12 and B7-1elicits potent antitumor effect and survival
advantage.
Oncolytic adenoviruses are currently being developed as
anticancer biological agents (1). Creating an armed therapeutic
viral platform, where the lytic property of viral infection
coupled to viral-mediated transgene delivery, may enhance
viral-based therapeutic potential. A clear advantage is the
amplification of a therapeutic gene, as replicating viruses
would be able to infect and deliver the gene of interest to
neighboring cells, ultimately enhancing the potential of the
viral-based therapy to deal with the complexity of a human
tumor.
Recently, interleukin (IL)-12 has shown to be one of the
most effective and promising antitumor cytokines (2, 3). IL-12
is a heterodimeric protein consisting of disulfide-linked 40- and
35-kDa subunits, and coexpression of both subunit cDNAs is
necessary for the production of biologically active protein.
Produced by activated macrophages, monocytes, dendritic cells,
and stimulated B lymphocytes, IL-12 has been shown to
augment the proliferation and cytolytic potential of both CTL
and natural killer (NK) cells (4). In general, IL-12 stimulates the
production of IFN-g production from T and NK cells. Local
expression of IL-12 has been shown previously to render tumor
cells susceptible to T-cell-mediated cytotoxicity, resulting in
inhibition of tumor growth and in some cases establishment
of a systemic immunity (5–7). Moreover, Lui et al. (8) reported
that systemic administration of naked DNA encoding IL-12
using hydrodynamics-based liver gene delivery induces signif-
icant antitumor effect. However, to date, the full therapeutic
effect, particularly in pre-established tumors, has been limited
mostly due to gene transfection of only one cytokine.
To achieve full T-cell activation, in addition to engaging its
receptor to the MHC, T cells require the interaction of CD28 on
its surface with a costimulatory molecule, such as B7-1 (CD80)
and B7-2 (CD86), located on professional antigen-presenting
cells (9, 10). Unfortunately, however, most tumor cells do not
express B7 family on its cell surface, thus resulting in T-cell
anergy (11, 12). Along this line, if cancer cells are engineered to
express B7-1, then enhanced T-cell proliferation and activation
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is seen. Using this approach, there has been several reports
describing successful induction of antitumor immune response,
in which B7-1-transfected tumor cells were used as a vaccine
(13, 14). It has also been shown that B7-1-expressing tumor
vaccines have been implicated to elicit CD8+ CTLs directly (15).
Interestingly, Guckel et al. (16) reported that expression of
IL-12 results in improvement in generating tumor-reactive
T cells. Further, Kubin et al. (17) showed that IL-12 expression
leads to a synergistic antitumor effect with a helper T (Th1)
pattern cytokine production. This synergistic relationship, in
which the effect of the combined costimuli is greater than their
additive effect, has been exploited with some success in the
generation of CTL against solid tumors (18–20).
In this study, we have used a combinatorial approach to
generate IL-12-expressing oncolytic adenovirus and IL-12- and
B7-1-coexpressing oncolytic adenovirus. We show that high
levels of IL-12 and B7-1 are expressed by these newly
engineered oncolytic adenoviruses in infected murine B16-
F10 cells. In addition, we show that intratumoral delivery of
oncolytic adenoviruses elicited significant antitumor effect as
well as prolonging survival in an immunocompetent murine
melanoma model. These antitumor effects were mediated by
the induction of immune cell–mediated cytotoxicity as shown
by intratumoral infiltration of CD4+ and CD8+ T cells, CTL
assay, and IFN-g enzyme-linked immunospot (ELISPOT) assay.
These results highlight the potential of oncolytic adenovirus
platform-based vectors in delivering synergistically interacting
cytokines for use in cancer gene therapy.
Materials andMethods
Cell lines and animals. All cell lines with the exception of Hep3B
and B16-F10, which were maintained in MEM (Life Technologies,
Grand Island, NY) and RPMI 1640 (Life Technologies), respectively,
were cultured in DMEM (Life Technologies) supplemented with fetal
bovine serum (10%; Life Technologies), L-glutamine (2 mmol/L),
penicillin (100 IU/mL), and streptomycin (50 Ag/mL). Human
embryonic kidney cell line expressing the adenoviral E1 region
(HEK293), brain cancer cell lines (U343 and U87MG), cervical cancer
cell line (C33A), liver cancer cell line (Hep3B), non–small lung cancer
cell line (A549), murine melanoma cell line (B16-F10), and mouse
fibroblast cell line (NIH3T3) were purchased from the American Type
Culture Collection (Manassas, VA). All cell lines were maintained 37jC
in a humidified atmosphere at 5% CO2.
For in vivo study, male C57BL/6 mice (6-8 weeks of age) were
purchased from Charles River Laboratories International, Inc. (Wil-
mington, MA). All mice were maintained in a laminar air-flow cabinet
at a room kept at 24 F 2jC temperatures and 40% to 70% humidity
with a 12-hour light/dark cycle under specific pathogen-free conditions.
All facilities are approved by the Association for Assessment and
Accreditation of Laboratory Animal Care, and all animal experiments
were conducted under the institutional guidelines established for the
Animal Core Facility at Yonsei University College of Medicine (Seoul,
South Korea).
Generation of adenoviruses expressing IL-12 and B7-1. To generate
IL-12-expressing oncolytic adenovirus, we first constructed an E1 shuttle
vector expressing murine IL-12 composed of p35 and p40. The IRES
region was excised from pcDNA3.1 (Invitrogen, Carlsbad, CA) using
EcoRI and subcloned into pcDNA3.1-p35 (Cytokine Bank, Chonbuk
University, Chunju, South Korea), generating a pcDNA3.1-p35/IRES.
The p40 gene was then excised from pcDNA3.1-p40 (Cytokine Bank,
Chonbuk University) using PmeI and Xho I and subcloned into
pcDNA3.1-p35/IRES predigested with EcoRV, resulting in pcDNA3.1-
IL-12. To produce IL-12-expressing E1 shuttle vector, Pme I-Xho I
fragments containing IL-12 expression cassette was excised from
pcDNA3.1-IL-12 and subcloned into pCA14/E1AE1B19 (21) predigested
Fig. 1. Characterizationofoncolytic adenoviruses.A, schematic representationof
oncolyticadenovirusesusedinthis study.YKL-1isatype5adenoviruswithnormalE1A
andE1B19kDabut E1B55kDadeleted;YKL-IL12 is composedof the IL-12 gene
drivenby the cytomegalovirus (CMV) promoter inserted into theE1regionofYKL-1;
YKL-IL12/B7 is composedof the IL-12 andB7-1genes drivenby theCMVpromoter
inserted into theE1andE3 regionofYKL-1, respectively.B,murine IL-12expression
level inB16-F10cells transducedwithYKL-IL12orYKL-IL12/B7.Cell culture
supernatantwas collectedat 48hours after infection, and the amountof IL-12was
quantifiedbyconventional ELISAkit. Results are representativeof three independent
experiments.Columns,meanofquadruplicate experiments; bars, SD.C,murineB7-1
expressionlevel inB16-F10cells transducedwithYKL-IL12/B7.Cellswere incubated
withanti-B7-1antibody.Solid line, phycoerythrin fluorescence.Values are themean
fluorescenceofB7-1-positive cells comparedwithnegative control.Dataare
representative fluorescencehistogramsof three independent experiments.D, invitro
cytopathiceffect.Monolayersgrownin24-wellplateswereinfectedwithAd-DE1(1),
YKL-1 (2),YKL-IL12 (3), orYKL-IL12/B7(4) at variousMOIs, andcellkillingwas
allowed toproceed for 6 to10days followedbycrystal violet staining to detect live
cells.Replication-incompetentAd-DE1servedas anegative control. Results are
representativeof experimentdone three times.The expressionof IL-12andB7-1did
not compromise theviralability to induce classic cytopathic effect.
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with EcoRV and SalI, generating a pCA14/E1AE1B19-IL-12 E1 shuttle
vector. The newly constructed pCA14/E1AE1B19/IL-12 E1 shuttle vector
was then linearized with NdeI digestion, and the adenoviral vector
pvmdl324BstBI was linearized with BstBI digestion. The linearized
pCA14/E1AE1B19/IL-12 E1 shuttle vector was then cotransformed into
Escherichia coli BJ5183 along with the NdeI-digested pvmdl324BstBI for
homologous recombination, generating a pYKL-IL12 adenoviral vector
(Fig. 1A). To generate an oncolytic adenovirus expressing IL-12 and B7-1
at the E1 and E3 region, respectively, we first constructed an E3 shuttle
vector expressing B7-1. The murine B7-1 gene was excised from pLNCX-
B7-1 (a kind gift from Dr. Richard Junghans, Harvard Medical School,
Boston, MA) using BstBI and ClaI and subcloned into the adenovirus
E3 shuttle vector, pSP72-E3 (22), creating a pSP72-E3/CMV-B7-1. The
newly constructed pSP72-E3/CMV-B7-1 shuttle vector was then linear-
ized with XmnI digestion and then cotransformed into E. coli BJ5183
together with the SpeI-digested pYKL-IL12 for homologous recombina-
tion, generating a pYKL-IL12/B7 adenoviral vector. To verify the
respective homologous recombinants, the plasmid DNA purified from
overnight E. coli culture was digested with HindIII, and the digestion
pattern was analyzed. The proper homologous recombinant adenoviral
plasmid DNA was then digested with PacI and transfected into 293 cells
to generate YKL-IL12 and YKL-IL12/B7 oncolytic adenoviruses. E1-
deleted replication-incompetent adenovirus (Ad-DEl) and E1B 55 kDa
deleted oncolytic adenovirus (YKL-1) were also prepared. All viruses
were propagated in 293 cells and purified by CsCl density purification,
dissolved in storage buffer (10 mmol/L Tris, 4% sucrose, 2 mmol/L
MgCl2), and stored at 80jC. Viral particle numbers were calculated
from measurements of absorbance at 260 nm (A260), where 1
absorbency unit is equivalent to 1012 viral particles/mL, and infectious
titers (plaque-forming units per milliliter) were determined by limiting
dilution assay on 293 cells. The multiplicity of infection (MOI) was
calculated from viral particle numbers. The particle/plaque-forming unit
ratio for YKL-1, YKL-IL12, and YKL-IL12/B7 were 40:1, 39:1, and 42:1,
respectively.
ELISA for IL-12 expression. IL-12 expression was determined using
an ELISA according to the manufacturer’s instructions (Endogen,
Woburn, MA). The flat-bottomed 96-well microtiter plates (Nunc
Maxisorp, Montgomery, TX) were coated with a rat anti-IL-12 antibody
(10 mg/mL) at 4jC overnight and blocked with bovine serum albumin
(4%) in PBS for 2 hours at 37jC. B16-F10 melanoma cells were plated
onto six-well plates at 1  104 per well and then infected with YKL-IL12
or YKL-IL12/B7 adenovirus at MOIs of 10 to 100. At 48 hours after
infection, supernatants were harvested and transferred to the wells of
anti-IL-12 antibody-coated microtiter plates. After incubation at 37jC
for 1 hour, the plates were then washed several times, and rat anti-IL-12
antibody conjugated with biotin was added. Color was developed using
an avidin-conjugated horseradish peroxidase and o-phenylenediamine
dihydrochloride substrate (Sigma, St. Louis, MO), and the reaction was
terminated by the addition of 2 N H2SO4. Absorbance was measured at
490 and 540 nm with a microplate reader (Molecular Devices Corp.,
Sunnyvale, CA). The amounts of IL-12 were quantified by interpolation
of a standard curve generated using known amounts of standard
recombinant IL-12 (Endogen).
Fluorescence-activated cell sorting analysis for B7-1 expression. B16-
F10 melanoma cells were seed onto 25-T culture flask at 1  106 per
well and then infected with YKL-IL12/B7 adenovirus at MOIs of 5 to
100. At 48 hours after infection, cells were detached with cell
dissociation solution (Sigma) and washed with PBS. Phycoerythrin-
conjugated hamster anti-mouse CD80 monoclonal antibody (Phar-
Mingen, San Diego, CA) was subsequently added at 4jC for 45 minutes.
After PBS washing, 500 AL PBS was added to do flow cytometric
analysis. Cells were analyzed on a FACScan (Becton Dickinson,
Sunnyvale, CA) using CellQuest software (Becton Dickinson). Live
cells were gated by forward and side scatter.
Cytopathic effect assay. To evaluate the cytopathic effect of oncolytic
adenoviruses, cells were plated onto 24-well plates at about 30% to
80% confluence and then infected with Ad-DE1, YKL-1, YKL-IL12, or
YKL-IL12/B7 adenovirus at MOIs of 0.1 to 1,000. Their killing effect was
monitored daily under a microscope. At the moment that cells infected
with any one of the virus exhibited complete cell lysis at low MOIs, the
dead cells were washed out, and cells on the plate were then stained
with 0.5% crystal violet in 50% methanol.
Antitumor effects of IL-12 and B7-1-expressing oncolytic adenovirus.
Tumors were implanted s.c. on the abdomen of C57BL/6 mice by
injecting B16-F10 murine melanoma cells (5  105) in 100 AL HBSS
(Life Technologies). When tumors reached a range of 80 to 100 mm3,
animals were randomized into four groups (PBS, YKL-1, YKL-IL12, and
YKL-IL12/B7) of 7 to 13 animals each, and treatment was initiated.
First day of treatment was designated as day 1. Adenoviruses or PBS was
given intratumorally (5  108 plaque-forming units per tumor in 20 AL
PBS) on days 1, 3, 5, 7, and 9. Tumor growth delay was assessed by
taking measurements of the length (L) and width (w) of the tumor on a
2- to 3-day interval. Tumor volume was calculated using the following
formula: volume = 0.523L(w)2. Tumor responses to each treatment
were compared using a log-rank test analysis (StatView software, Abacus
Concepts, Inc., Berkeley, CA). The percentage of surviving mice was
determined by monitoring the tumor growth–related events (tumor
size, >3,000 mm3) over a period of 40 days. Survival curve was then
plotted against time after treatment. Differences in survival were
considered statistically significant when P <0.05.
Measurement of IL-12 and IFN-g expression in tumor tissue. Tumor
tissues were removed from mice treated with PBS, YKL-1, YKL-IL12, or
YKL-IL12/B7 and snap frozen in liquid nitrogen. Tissues were
homogenized (ART-MICCRA D-8, ART-moderne Labortechnik, Munich,
Germany) and treated with protein inhibitor cocktail (Sigma). Homo-
genates were centrifuged in a high-speed microcentrifuge for 10 minutes
and analyzed for total protein content using a bicinchoninic acid protein
assay reagent kit (Bio-Rad, Hercules, CA). Levels of IL-12 and IFN-g in
supernatant were determined by ELISA (Endogen). Cytokine results
were normalized relative to the total protein concentration in each
tumor and were calculated as picograms per milligram of total protein.
Fluorescence-activated cell sorting analysis of splenocytes. To assess
T-cell and dendritic cell population, spleens were harvested 3 to 5 days
after last viral injection into the B16-F10 tumor-bearing mice. Spleens
were minced into single-cell suspensions in PBS plus 2% FCS and
treated with EDTA-ammonium chloride solution (0.15 mol/L NH4Cl,
1 mmol/L KHCO3, and 0.1 mmol/L EDTA) to remove RBC. To assess
T-cell population, fluorescence-activated cell sorting was done on a
FACScan after labeling 1  106 splenocytes with FITC-conjugated
hamster anti-mouse CD3q monoclonal antibody (145-2C11, DiNonA,
Seoul, South Korea), phycoerythrin-conjugated rat anti-mouse CD4/
L3T4 monoclonal antibody (GK1.5, DiNonA), or phycoerythrin-
conjugated rat anti-mouse CD8/Lyt-2 monoclonal antibody (53-6.7,
DiNonA). To determine dendritic cell population, splenocytes were
stained with rat anti-mouse CD11b/Mac-1 (3A33, Southern Biotech,
Birmingham, AL), hamster anti-mouse FITC-labeled CD11c (HL3,
PharMingen), rat anti-mouse CD80 (RMMP-1, Serotec, Oxford, United
Kingdom), or rat anti-mouse CD86 (GL-1, Southern Biotech) as a
primary antibody and goat anti-rat IgG-phycoerythrin (Southern
Biotech) as a secondary antibody. Cells were then fixed with 1%
paraformaldehyde in PBS for fluorescence-activated cell sorting
analysis. Live cells were gated using forward and side scatter. Isotype-
matched control antibodies were used to set voltages and positive
controls were used to set compensation.
Cytotoxicity assay. The cytolytic activity of CTL was determined by
standard 4-hour 51Cr release assays. Spleens were removed aseptically
3 to 5 days after last viral injection into the B16-F10 tumor-bearing
mice, and unicellular splenocytes were prepared as same as in the
method of fluorescence-activated cell sorting analysis of spleen cells.
RBC-depleted splenocytes were then cocultured with irradiated B16-F10
or NIH3T3 cells (5,000 rad) for 5 days in the presence of recombinant
human IL-2 (100 units/mL). Following this coculture, splenocytes as
effector cells were recovered and incubated in triplicate with 51Cr-
labeled B16-F10 or NIH3T3 cells (1.5  106) as target cells at four
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different E:Ts (10:1, 20:1, 30:1, and 50:1). After 4 hours of incubation
at 37jC, the supernatant was harvested and radioactive release was
measured. The percentage of cytotoxicity was calculated as [(cpm
experimental release  cpm spontaneous release) / (cpm maximum
release  cpm spontaneous release)]  100. The extent of maximal
release of the incorporated chromium was determined by detergent lysis
of the labeled cells, and spontaneous release was determined by
incubation of the labeled cells without effector cells. The cytolytic
activity of CTL was also visualized by staining live B16-F10 cells after
coculture with splenocytes. B16-F10 cells (target) were first plated onto
24-well plates at 3  104 per well and then mixed with splenocytes
(effector) derived from B16-F10 tumor-bearing mice at three different
E:Ts (10:1, 30:1, and 100:1). The mixtures of target and effector cells
were then incubated for 4 to 8 days at 37jC followed by staining with
0.5% crystal violet in 50% methanol.
IFN-g ELISPOT assay. To determine the frequency of antigen-
specific cytokine-producing cells, ELISPOT assay was carried out. RBC-
depleted splenocytes were first restimulated by coculturing with
irradiated B16-F10 (5,000 rad) tumor cells for 3 days in the presence
of recombinant human IL-2 (100 units/mL). Serial dilutions of the
stimulated splenocytes (3  104, 6  104, 3  105, 6  105, 1.2  106,
and 2.4  106) were then incubated in anti-IFN-g monoclonal
antibody-coated plates. Each experimental condition was plated in
triplicate and incubated at 37jC/5% CO2 for 24 hours. Cells were
removed, and the plates were washed three times with PBS containing
1% fetal bovine serum and 0.05% Tween 20. Biotinylated secondary
anti-IFN-g monoclonal antibody (50 AL) was added to each well and
incubated in the dark at room temperature for 2 hours. The plates were
washed with PBS containing 1% fetal bovine serum and 0.05% Tween
20, and then 50 AL streptavidin-horseradish peroxidase was added to
each well and incubated at room temperature in the dark for 1 hour.
Washing was repeated and a colorimetric reaction was initiated by the
addition of substrates from a commercial kit (Endogen). The colored
spots, representing IFN-g-producing cells, were counted with a KS
ELISPOT (Zeiss-Kontron, Jena, Germany) and confirmed by the
computer-based immunospot system (AID Elispot Reader System,
version 3.4, Autoimmun Diagnostika GmbH, Strassberg, Germany).
The results were similar for manual and computer-based counting. All
wells were averaged and normalized by comparing the ratio of antigen-
specific spots to negative control spots.
Histology and immunohistochemistry. Tumor tissues for histologic
examination were fixed in 10% neutral buffered formalin, processed
to paraffin embedment, and cut into 4-Am sections. Representative
sections were stained with H&E and examined by light microscopy.
To identify lymphocytes, tumor tissues were frozen in OCT
compound (Sakura Finetec, Torrance, CA) and cut into 10-Am
sections. The cyrosections were blocked with 1% bovine serum
albumin in PBS and stained with purified rat anti-mouse CD4
monoclonal antibody (PharMingen) or purified rat anti-mouse CD8
monoclonal antibody (PharMingen) as a primary antibody and then
with biotin-conjugated goat anti-rat IgG (PharMingen) as a secondary
antibody. Diaminobenzidine/hydrogen peroxidase (DAKO, Carpin-
teria, CA) was used as the chromogen substrate. All slides were
counterstained with Meyer’s hematoxylin. The average number of
CD4+ and CD8+ T cells per field was determined under a light
microscope at 400 magnification.
Statistical analysis. The data were expressed as mean F SE.
Statistical comparison was made using StatView software and the
Mann-Whitney test (nonparametric method). The criterion for statis-
tical significance was taken as P < 0.05.
Results
Oncolytic adenovirus-mediated IL-12 and B7-1 expression. To
generate the two oncolytic adenoviruses expressing either
IL-12 alone or IL-12 plus B7-1, murine IL-12 and B7-1 genes
were placed in the E1 and E3 region of E1B 55 kDa deleted
oncolytic adenovirus, YKL-1, respectively, generating YKL-IL12
and YKL-IL12/B7 adenoviruses (Fig. 1A). To determine the
level of IL-12 expression from these adenoviruses, B16-F10
melanoma cells were infected with YKL-IL12 and YKL-IL12/
B7 at different MOIs. The results showed a significant
expression of the virally transduced IL-12 gene, whose levels
increased in a dose-dependent manner up to MOI of 100
(Fig. 1B). Notably, the IL-12 expression from YKL-IL12/B7
infection at an MOI of 20 and 100 were 1,472 F 13 and
3,050 F 13 pg/mL, respectively, whereas those from YKL-
IL12 were 1,012 F 20 and 2,209 F 39 pg/mL. Thus,
additional expression of B7-1 in the E3 region did not affect
IL-12 expression. Next, the expression level of B7-1 was
assessed by flow cytometric analysis 48 hours after infection
with YKL-IL12/B7 in B16-F10 cells. As shown in Fig. 1C, B7-
1 was also strongly expressed on the cell surface of B16-F10
Fig. 2. Evaluation of therapeutic effect on established tumor model. A, tumor
growth response following intratumoral injection of PBS,YKL-1,YKL-IL12, or
YKL-IL12/B7. B16-F10 cells (5  105) were injected s.c. into the abdomen of male
C57BL6 mice.When tumor size reached to about 80 to100 mm3, tumors were
injected with the following: PBS (n = 13),YKL-1 (n = 10),YKL-IL12 (n = 7), or
YKL-IL12/B7 (n = 7). Adenoviruses [5  108 plaque-forming units (PFU)] were
injected intratumorally five times every other day.Tumor growth was then evaluated
by microcaliper measurements done two to three times weekly.The difference
between all experimental and PBS control groups is statistically significant (day 9;
P < 0.001for all three adenoviruses). B, long-term survival of mice bearing B16-F10
tumors following treatment with PBS,YKL-1,YKL-IL12, orYKL-IL12/B7.The
percentage of mice viability was determined by monitoring the tumor growth ^
related events (tumor size >3,000 mm3) over a period of 40 days.The survival
advantage for theYKL-IL12- andYKL-IL12/B7-treated animals was statistically
significant compared with PBS andYKL-1 (P < 0.001). Results are representative
data from one of two independent experiments.
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infected with YKL-IL12/B7, whose level of expression was
directly proportional to the MOIs used for infection,
indicating that the B7-1 protein expressed by this oncolytic
adenovirus was properly presented on the cell surface.
IL-12 and B7-1 expression does not inhibit viral replica-
tion. To determine whether IL-12 and B7-1 expression would
alter viral replication, YKL-IL12 and YKL-IL12/B7 oncolytic
adenoviruses were examined for their ability to induce viral
cytopathic effects in a variety of cell lines. In general, murine
cells tended to be less sensitive or even resistant to adenoviral
infections compared with human cells. Thus, we used five
different types of human cancer cell lines (U343, U87MG,
C33A, Hep3B, and A549) from varying histologic types, in
addition to the murine melanoma cell line (B16-F10) in the
cytopathic effect assay. Cells were infected with YKL-1 (cognate
oncolytic adenovirus), YKL-IL12, or YKL-IL12/B7 adenovirus
along with Ad-DE1 as a negative control. Next, the subjected
cells were treated with crystal violet to show relative extent of
cell lysis. As seen in Fig. 1D, YKL-IL12- and YKL-IL12/B7-
induced cytopathic effect appeared to be slightly faster in
U87MG and Hep3B compared with YKL-1. This result was
repeated over several independent experiments, indicating that
IL-12 and B7-1 expression does not inhibit viral replication.
Similarly, the cytopathic effect induced by YKL-IL12/B7 was
comparable with that induced by YKL-IL12, showing that viral
replication of oncolytic adenovirus expressing both IL-12 and
B7-1 was not decreased compared with oncolytic adenovirus
expressing IL-12 alone. This observation is consistent with the
result of IL-12 expression level of YKL-IL12 and YKL-IL12/B7
oncolytic adenoviruses.
Comparison of the relative antitumor effect of YKL-IL12 and
YKL-IL12/B7. We next evaluated the relative antitumor effect
of oncolytic adenovirus expressing either IL-12 alone or IL-12
plus B7-1 in B16-F10 melanoma model established in C57BL/6
mice. As seen in Fig. 2A, control tumors which received PBS
showed robust growth, resulting in a tumor volume of 2,481 F
885 mm3 by 9 days after initial injection. Subsequently by
20 days after treatment, all mice in the PBS control group were
not viable (Fig. 2B). In marked contrast, the tumor growth was
severely suppressed in mice injected with YKL-IL12 (P < 0.01
versus PBS or YKL-1 group) or YKL-IL12/B7 (P < 0.01 versus
PBS or YKL-1 group). More specifically, the average tumor
volume at 20 days after injection for YKL-IL12 and YKL-IL12/B7
groups were 274 F 211 and 46 F 22 mm3, respectively,
whereas tumors treated with YKL-1 grew progressively large,
reaching to an average size of 2,666 F 793 mm3. Further, 3 of
the 7 animals that received YKL-IL12/B7 remained viable
50 days after initial treatment (Fig. 2B). In contrast, no animal
in YKL-1 and YKL-IL12 group was viable in the same time
period. The survival advantage conferred by YKL-IL12/B7
therapy was statistically significant when compared with either
of the YKL-1 and YKL-IL12 groups (P < 0.001 versus YKL-1
group and P < 0.05 versus YKL-IL12).
In vivo expression of IL-12 and IFN-g. To evaluate the level
of IL-12 and IFN-g produced in YKL-IL12- or YKL-IL12/B7-
treated mice, tumor tissues were obtained 5 days after final
viral injection. Figure 3 shows IL-12 and IFN-g in picogram per
milligram of total protein from three independent experi-
ments. In PBS-treated and YKL-1 adenovirus-treated tumor
cells, only a trace amount of IL-12 was detected (21.1 F 144.1
and 249.4 F 40.7 pg/mg, respectively). In comparison, YKL-
IL12 adenovirus-treated or YKL-IL12/B7 adenovirus-treated
tumors exhibited high concentration of IL-12 (3,412.2 F
316.5 pg/mg for YKL-IL12 and 9,364.8 F 276.7 pg/mg for
YKL-IL12/B7; Fig. 3A). Similarly, YKL-IL12- or YKL-IL12/B7-
treated mice produced significantly greater level of IFN-g
(7,289.8 F 5,130.3 pg/mg for YKL-IL12 and 21,800.0 F
694.6 pg/mg for YKL-IL12/B7) compared with PBS-treated mice
of 259.8 F 857.0 pg/mL and YKL-1-treated mice of 573.6 F
2,393.1 pg/mg (Fig. 3B). Finally, in relative comparison, YKL-
IL12/B7-treated tumors produced significantly higher level of
both IL-12 and IFN-g than YKL-IL12.
Generation of tumor-specific CTL. To establish that tumor
regression is associated with the generation of tumor-specific
immune response, 51Cr release assay was carried out. Spleno-
cytes obtained from YKL-IL12- or YKL-IL12/B7-treated mice
showed potent B16-F10-specific lytic activity on day 5 after
exposure. CTL killing of splenocytes from mice treated with
YKL-IL12 or YKL-IL12/B7 was 39.8% and 41.0% at an E:T
of 30:1 and 44.5% and 50.6% at an E:T of 50:1, respectively,
with no measurable background (Fig. 4A). At the same time,
however, splenocytes from mice treated with PBS or YKL-1 did
not show any significant B16-F10-specific lytic activity. The CTL
activity of splenocytes from mice treated with YKL-IL12 or
YKL-IL12/B7 was specific to a given tumor, as no CTL activity
could be detected when NIH3T3 cells were used as target cells
(data not shown).
Fig. 3. Cytokine production after treatment of PBS,YKL-1,YKL-IL12, or
YKL-IL12/B7.Tumor tissue was collected 5 days after final viral injection, and
ELISAwas done to determine the levels of IL-12 (A) and IFN-g (B) in tumor tissues.
Data are representative of three independent experiments.
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Fig. 4. Generation of antitumor specific immune response.Tumor-bearing mice received three intratumoral injections of PBS,YKL-1,YKL-IL12, orYKL-IL12/B7. A, 51Cr release
from B16-F10 target cells was measured after incubation with in vitro ^ stimulated splenocytes frommice treated with PBS,YKL-1,YKL-IL12, orYKL-IL12/B7. Points, mean of
quadruplicate experiments; bars, SD. Results are representative of three independent experiments. B, visualization of tumor cell killing effect of CTL. Splenocytes (effector)
obtained from mice injected withYKL-IL12 orYKL-IL12/B7 showed a significantly higher lysis of B16-F10 cells (target). However, most of cells remained viable when those of
PBS- andYKL-1-treated mice were cocultured with B16-F10 target cells in the same time period. C, ELISPOTassay for IFN-g. Adenoviruses-infected animals were sacrificed
3 days after final viral injection. Results are presented as number of spots assayed in the condition as described in Materials and Methods.
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The cytolytic activity of CTL was also visualized by staining
live B16-F10 cells after coculture with splenocytes. B16-F10
cells (target) were mixed and cocultured for 4 to 8 days with
splenocytes (effector) derived from B16-F10 tumor-bearing
mice treated with PBS, YKL-1, YKL-IL12, or YKL-IL12/B7 at
three different E:Ts (10:1, 30:1, and 100:1). As seen in Fig. 4B,
splenocytes derived from mice treated with YKL-IL12 or YKL-
IL12/B7 exerted higher tumor cell killing potency over those
from YKL-1-treated mice. Specifically, when cocultured for
6 days, splenocytes from mice treated with YKL-IL12 or YKL-
IL12/B7 induced rapid target cell killing, resulting in complete
eradication of cells on the plate. However, most cells remained
viable and stained with crystal violet when those of PBS- and
YKL-1-treated mice were cocultured with B16-F10 target cells in
the same time period.
To further delineate the tumor-specific immune responses in
mice, number of cells expressing IFN-g, a cytokine secreted by
CTL, was evaluated through IFN-g ELISPOT assay. Splenocytes
were isolated aseptically on day 3 after final viral injection from
C57BL6mice treated as described above and were serially seeded
at a concentration from 3  104 to 2.4  106 cells per well into
the anti-IFN-g antibody-coated 96-well plate. The number of
IFN-g-secreting cells was then subsequently analyzed. As
presented in Fig. 4C, the frequency of IFN-g-secreting immune
cells recovered from mice injected with YKL-IL12/B7 was
significantly greater than that rescued from mice given YKL-
IL12 or YKL-1. Specifically, the number of IFN-g-secreting cells
obtained from mice injected with YKL-IL12/B7 at a concentra-
tion of 3  105 splenocytes was about 4.4- and 5.4-fold higher
than that of YKL-IL12 and YKL-1, respectively. These results
suggest that animals treated with YKL-IL12/B7 generated higher
tumor-specific immune responses than those treated with YKL-
IL-12 or YKL-1, showing synergy of IL-12with B7-1 in promoting
the IFN-g production.
Alteration in splenic CD4+/CD8+ T-cell, macrophage, and
dendritic cell populations. Purified splenocytes from mice at 3
to 5 days following final viral injection were first analyzed to
determine the population of CD4+ and CD8+ T-cell. Analysis
revealed a slight elevation in the frequency of CD4+ (29.69%
and 34.78%) T cells in the YKL-IL12- and YKL-IL12/B7-treated
mice, respectively, compared with YKL-1-treated mice (25.15%;
Fig. 5A). Similarly, the frequency of CD8+ T cells was also
marginally increased in the mice treated with YKL-IL12/B7
(26.11%) compared with those treated with YKL-1 (22.43%).
These results show the increased number of T lymphocytes
capable of inducing cancer-specific immune response in
response to coexpression of IL-12 and B7-1. To further evaluate
macrophage and dendritic cell population, which are the most
potent antigen-presenting cells, splenocytes were also analyzed
for their expression of CD11b, CD11c, CD80, and CD86 by
flow cytometry. As shown in Fig. 5B, YKL-IL12- and YKL-IL12/
B7-treated splenocytes expressed increased level of activation/
costimulatory molecules when compared with PBS- or YKL-1-
treated splenocytes. In particular, the expression level of CD11c
and CD86 of YKL-IL12/B7-treated splenocytes was notably
higher than those of YKL-IL12-treated splenocytes. These results
suggest that adenovirus coexpressing IL-12 and B7-1 induced
more efficient antigen-presenting cell maturation in vivo than
adenovirus expressing IL-12 alone.
Increased CD4+ and CD8+ T-cell infiltration in YKL-IL12 and
YKL-IL12/B7 adenovirus-treated tumors. Histologic analysis
with H&E staining was carried out to study lymphocyte
infiltration into tumor tissues. As seen in Fig. 6A, YKL-IL12-
and YKL-IL12/B7-treated tumors showed visibly smaller
size with significantly higher immune cell infiltration than
YKL-1-treated controls. In particular, for tumors treated with
YKL-IL12/B7, comparatively extensive lymphocytic infiltration
intermingled with nuclear debris was observed not only around
but also inside the tumor tissue. Moreover, in the YKL-IL12-
and YKL-IL12/B7-treated group, almost all of the remaining
tumor tissues appeared to be necrotic.
The involvement of CD4+ and CD8+ lymphocyte subsets in
the antitumor response was further studied using antibodies
with specificities for CD4+ and CD8+ T-cell markers. Higher
Fig. 5. Assessment of T-cell and dendritic cell population. A, fluorescence-
activated cell sorting analysis after double staining by immunofluorescence with
anti-CD3/anti-CD4 and CD3/anti-CD8 monoclonal antibodies of splenocytes from
mice whose s.c. B16-F10 tumors had been treated with PBS,YKL-1,YKL-IL12, or
YKL-IL12/B7.Top right quadrants, percentages of the CD3+CD4+ and CD3+CD8+
T-cell population. Results are representative of several independent experiments, in
which proportions of CD3+CD4+ or CD3+CD8+ Tcells were consistent.
B, splenocytes were analyzed for dendritic cell phenotype (CD11b, CD11c, CD80,
and CD86) by flow cytometry after treatment with PBS,YKL-1,YKL-IL12, or
YKL-IL12/B7. Cells were stained with indicated monoclonal antibodies or isotype
controls and analyzedon anopengate for phenotype by fluorescence-activated cell
sorting.Values are the relative mean fluorescence of stained cells over controls.
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frequencies of CD4+ and CD8+ T cells were observed in both
the center and the border zones of the tumors treated with
YKL-IL-12/B7 when compared with YKL-IL12-treated tumors
(Fig. 6B). In contrast, the tumors of the YKL-1 control groups
contained only minor levels of CD4+ and CD8+ T cells.
Discussion
Direct administration of immunostimulatory cytokine genes
to modify cytokine profile in situ has been an attractive and
effective approach in inhibiting tumor growth. Several cyto-
kines, including IL-2, IL-12, IL-18, granulocyte macrophage
colony-stimulating factor, IL-12, IFN-a, and IFN-g have shown
significant antitumor effects (23–26). Among these, IL-12 has
become the most promising cytokine for immunotherapy of
many cancers due to its pleiotropic effects showed both in vitro
and in vivo . IL-12 is believed to promote antitumor immunity
by stimulating Th1 immune response by increasing MHC
expression and up-regulating the cytotoxic activity of NK and
CD8+ T cells (27, 28). B7-1, on the other hand, provides potent
antigen-independent costimulatory signal to T cells and lowers
the threshold for T-cell activation, resulting in an increase in the
production of Th1-associated cytokines, including IL-2, IL-12,
and IFN-g, important in promoting antitumor CTL responses
(17, 29). Murphy et al. (20) reported that proliferation by
terminally differentiated Th1 clones, in contrast to naive T cells,
requires stimulation via membrane-bound B7-1 and IL-12.
Moreover, it has been also shown that coexpression of IL-12
and B7-1 synergistically improves T-cell activation and the
production of Th1 pattern cytokines (17).
In the present study, we examined the antitumor efficacy
potential of a single oncolytic adenovirus vector expressing
both IL-12 and B7-1. IL-12 and B7-1 expression was first
examined in B16-F10 cells as murine cells are resistant to
infection by human adenovirus. As shown in Fig. 1, virally
induced IL-12 and B7-1 genes were expressed in this murine
cell line in a dose-dependent manner. Further, IL-12 and B7-1
expression did not compromise viral ability to induce classic
cytopathic effect in infected cells or abolish the ability to
produce progeny virus. The therapeutic efficacy of YKL-IL12 or
YKL-IL12/B7 adenovirus was then evaluated in immunocom-
petent mice bearing murine melanoma B16-F10 tumors.
Significant inhibition of tumor growth resulted in mice treated
with YKL-IL12 or YKL-IL12/B7 adenovirus. More specifically,
YKL-IL12/B7 oncolytic adenovirus showed a higher incidence
of complete tumor regression compared with the analogous
vector, YKL-1, or YKL-IL12. Significant survival advantage was
also seen in response to YKL-IL12/B7. These results suggest that
using an oncolytic adenovirus in combination with expression
of IL-12 and B7-1 result in greater potent antitumor effect than
either YKL-1 or YKL-IL12.
To investigate whether the generation of tumor-specific
T-cell-mediated immune responses was responsible for the
observed antitumor effect, CTL assay and IFN-g ELISPOT assay
were carried out. Activation of CD8+ T cells and stimulation of
CTL activity are involved in antitumor effect induced by IL-12
in different animal tumor models (30, 31). In our system, we
observed that cytolytic activity of CTLs cultured from spleno-
cytes of mice treated with YKL-IL12 or YKL-IL12/B7 was
significantly elevated against inoculated tumor compared with
Fig. 6. Histologic and
immunohistochemical analysis.
Formalin-fixed tumor tissues were
embedded in paraffin and sectioned.
A, H&E-stained tumor sections. Original
magnifications,1, 40, and 400.
B, frozen tumor sections were stained with
anti-CD4 or anti-CD8 antibodies.
Immunohistochemical analysis of these
sections showed enhanced infiltration of
CD4+ and CD8+ Tcells in tumor tissue in
YKL-IL12/B7-treated mice compared with
YKL-1- orYKL-IL12-treated tumor. Original
magnification, 400.
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that with PBS or YKL-1. Moreover, the frequencies of IFN-g-
positive cells measured with the IFN-g ELISPOT assay
correlated with the corresponding tumor cell–specific killing
measured by 51Cr release assay. In agreement with these results,
the histologic and immunohistochemical studies also showed
massive infiltration of CD4+ and CD8+ T cells into the tissues
surrounding the necrotic area of the tumor after in situ delivery
of YKL-IL12/B7 than those in the tumor tissue treated with
YKL-1 or YKL-IL12. These results suggest that IL-12 and B7-1
play a critical and interactive role in promoting tumor-specific
immunity.
In several systems, it has been shown that IFN-g is the
main downstream mediator of the IL-12 antitumor efficacy
(32–34). IL-12-activated cells, such as antigen-presenting
cells, T cells, or NK cells, produce IFN-g, and IFN-g in turn
induces effects not only on the immune system but also on
tumor cells, making them susceptible to be lysed by CTLs
(35). Antitumor effects of IL-12 were reported in a variety of
cancer models. In a hepatocellular carcinoma model, f50%
of mice infected intratumorally with 5  109 plaque-forming
units of IL-12 expressing adenovirus showed complete
regression after 2 weeks of treatment, accompanied by local
secretion of IL-12 and IFN-g (36). Consistent with these
findings, we found that high levels of IL-12 and IFN-g are
produced in mice after injection with YKL-IL12 or YKL-IL12/
B7. The high IFN-g induction following treatment with YKL-
IL12 or YKL-IL12/B7 supports the notion that IL-12 produced
by tumor cells is biologically active and exerts its character-
istic immunoregulatory functions. It is interesting note that
the level of IFN-g expression by YKL-IL12 (7,289 pg/mg) or
YKL-IL12/B7 (21,800 pg/mg) is far greater than what was
reported previously by Mazzolini et al. (200 pg/mg; ref. 31).
These data indicate that, compared with conventional non-
replicating vector systems, these newly engineered oncolytic
adenoviruses are much more efficient in driving cytokine
expressions, leading potent antitumor immune responses.
Moreover, IL-12 and IFN-g levels produced in tumors treated
with YKL-IL12/B7 was significantly greater than those treated
with YKL-IL12, suggesting that the expression of IL-12 and
B7-1 at the site of the tumor plays an important role in
inducing antitumor responses. This observation is consistent
with the reported synergistic effect between IL-12 and B7-1 as
reported in murine mammary adenocarcinoma model show-
ing that coinjection of two different adenovirus vectors
expressing either IL-12 or B7-1 induced higher antitumor
effect than injection with either vector alone (18). Likewise,
it has been reported that the effectiveness of IL-12 in a
poorly immunogenic pancreatic tumor model that lack
endogenous B7-1 expression can be significantly potentiated
by B7-1 costimulation (37).
Higher doses of IL-12 not only elicit potent antitumor effect
but also induce dose-dependent toxicity, including ascites, dry
mucous membranes, lack of grooming, and occasional death
(<5%). Fatal toxicity in a phase II human clinical trial using
systemic administration of recombinant IL-12 has also been
reported (38). Thus, the use of IL-12 as an antitumoral agent by
means of systemic administration has been hampered by these
cases of serious side effects. In an orthotopic hepatocellular
carcinoma and a bladder carcinoma models, intratumoral
injection with IL-12 expressing adenovirus resulted in very
potent antitumor effect, but no detectable serum level of IL-12
or IFN-g was documented (36, 39). Our data are consistent
with these observations, as we found no evidence of increased
IL-12 or IFN-g serum levels at 3 days after intratumoral
injection of YKL-IL12 or YKL-IL12/B7 oncolytic adenovirus nor
was there any evident toxicity. Thus, we find that local delivery
of IL-12 by oncolytic adenovirus would endow higher local
synthesis of IL-12 in tumor bed, resulting in potent antitumor
effects without accompanying toxicities.
Taken collectively, our data suggest that combination of
oncolysis and the enhancement of antitumor immune response
by oncolytic adenovirus expressing both IL-12 and B7-1 elicits
potent antitumor effect. The YKL-IL12/B7 adenovirus showed
augmented and prolonged effect in suppressing tumor growth
in vivo , in contrast to the YKL-1 adenovirus that only showed
limited and temporary antitumor effect. Moreover, YKL-IL12/
B7 adenovirus elicited higher survival advantage compared
with YKL-IL12. The therapeutic advantage of YKL-IL12/B7
would be greatly enhanced in a human system as human tumor
cells are much more permissive to adenoviral infection and
replication. Because the therapeutic value of YKL-IL12/B7
adenovirus has been verified to be very high, further studies
are being planned to investigate the application of this
adenovirus for cancer therapy, especially in preventing metas-
tasis and secondary tumorigenesis.
In conclusion, the findings of this study show the effective-
ness of augmenting the immune response against tumors with
oncolytic adenovirus expressing both IL-12 and B7-1. The
present study provides further support for the use of oncolytic
adenovirus in immunogene therapy in combating cancer and
particularly for cancer-specific delivery of cooperatively inter-
acting immunomodulatory genes in a single vector. Overall,
given the results shown in this study, oncolytic adenovirus-
mediated IL-12 and B7-1 gene transfer may open promising
avenues to effective and better tolerated immunogene therapy
in combating cancer.
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